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ABSTRACT
Up to 50% of infants present with symptoms of regurgitation, infantile colic and/or
constipation during the first 12 months of life. Although they are often classed as functional
disorders, there is an overlap with cows’ milk allergy. We present practical algorithms for the
management of such disorders, based on existing evidence and general consensus, with a
particular focus on primary health care. Management consists of early recognition of
warning signs of organic disease, parental reassurance and nutritional strategies.
Conclusion: The proposed algorithms aim to help healthcare providers manage frequent
gastrointestinal and cows’ milk-related symptoms in infants safely and effectively.
INTRODUCTION
Although functional gastrointestinal disorders (FGIDs),
such as regurgitation, infantile colic and constipation, are
considered to be benign conditions, they occur in up to 50%
of infants and are often frustrating for parents and carers.
Each of these FGIDs occurs in 20–25% of infants, who may
present with a combination of symptoms (1).
Functional gastrointestinal symptoms are considered to
be transient, self-limiting conditions. However, limited data
suggest that symptoms such as infantile colic may be
associated with recurrent abdominal pain, migraine, allergic
disorders, sleep disturbances and maladaptive behaviour,
such as aggressiveness, later in life (2).
Abbreviations
CMA, Cows’ milk allergy; ESPGHAN, European Society of
Paediatric Gastroenterology, Hepatology and Nutrition; FGID,
Functional gastrointestinal disorders; GOR, Gastro-oesophageal
reflux; IgE, Immunoglobulin E; NASPGHAN, North American
Society of Paediatric Gastroenterology, Hepatology and Nutri-
tion Society of Paediatric Gastroenterology, Hepatology and
Nutrition.
Key notes
 Up to 50% of all infants present with symptoms of
regurgitation, infantile colic and/or constipation during
the first 12 months of life.
 We present practical algorithms for the management of
frequent gastrointestinal and cows’ milk-related symp-
toms, based on existing evidence and general consen-
sus, with a particular focus on primary health care.
 The algorithms focus on early recognition of the
warning signs of organic disease, parental reassurance
and nutritional strategies.
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The Rome III consensus has proposed diagnostic criteria
for these symptoms, but not for the management of them
(3). Functional gastrointestinal symptoms are not a reason
to stop breastfeeding and almost half of all infants who are
formula-fed have at least one change of formula because of
gastrointestinal symptoms during their first six months of
life (4). This reflects the anxiety of parents and the search
for a remedy by both the parents and the doctors. The
natural course of these symptoms is for them to sponta-
neously disappear.
Children with cows’ milk allergy (CMA) can present with
one or more of the above symptoms and the clinical
discrimination between FGID and CMA may be challeng-
ing (5). Symptoms of CMA are nonspecific (5) and it is
difficult for primary healthcare providers to diagnose CMA.
Therefore, the preferred terminology is cows’ milk-related
symptoms, as this does not differentiate between FGID and
CMA as the cause of the symptoms. Because of the long-
term impact of a diagnosis of CMA on later health, such as
an increased risk for other atopic manifestations or diseases
(6), this diagnosis should only be made by specialists such
as paediatric allergists or appropriately experienced gas-
troenterologists. Asthma, allergic rhinitis and eczema are
more common in children with a history of CMA than
would be expected in the general population (6). While the
self-reported lifetime prevalence of CMA is 6% (5.7–6.4),
the prevalence of CMA defined by a positive food challenge
is only 0.6% (0.5–0.8) (7).
This paper gives practical advice that will enable primary
healthcare providers to recognise and manage common
FGID and cows’ milk-related symptoms in infants more
effectively. Practical recommendations and algorithms have
been developed and discussed. These may need to be
adapted to account for local circumstances and individual
patient situations.
METHODS
The authors did not aim to replace the evidence-based
guidelines of the North American Society of Paediatric
Gastroenterology, Hepatology and Nutrition Society of
Paediatric Gastroenterology, Hepatology and Nutrition
(NASPGHAN) or the European Society of Paediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN)
on CMA, gastro-oesophageal reflux (GOR) or constipation
(5,8,9). We searched MEDLINE, Embase, the Cochrane
Database of Systematic Reviews, the Cochrane Central
Register of Controlled Clinical Trials and PubMed from the
end of the literature searches mentioned in the ESPGHAN
guidelines on cow’s milk allergy (2012) and the
NASPGHAN/ESPGHAN guidelines on gastro-oesopha-
geal reflux and constipation (2009 and 2014, respectively)
up to October 2014. With regard to infantile colic, the
literature was searched for papers not included in three
systematic reviews (10–12). Our paper provides a follow-up
of the consensus algorithms that were developed by Belgian
paediatric gastroenterologists (13). The authors of this
paper, who come from different parts of the world, made
recommendations based on the evidence, when it was
available, and on the consensus if the evidence was missing.
The practical recommendations contained in this paper
should be applicable worldwide.
In November 2014 the Gastroenterology Committee of
ESPGHAN discussed the contents of this paper in detail
and voted on the statements during a face-to-face meeting.
This group decided to include additional key opinion
leaders, who participated in electronic discussions and
voting. Finally, the statements were given to another
selected group of experts who only participated in the
voting. As a result, 22 key opinion leaders from different
regions of the world participated in the voting.
To reach a consensus, we used a structured method that
had previously been shown to be effective (9,14). Consensus
was formally achieved through a nominal group technique,
which is a structured quantitative method. The group
consisted of 22 members who voted anonymously. Before
the voting took place, the statements were reviewed by each
co-author until agreement was reached. A nine-point scale
was used, ranging from one for strongly disagree to nine for
fully agree (15). It was decided beforehand that consensus
was deemed to be reached if more than 75% of the votes
were scores of six, seven, eight or nine. A vote of six and
above meant agreement, with nine being an expression of
stronger agreement than six.
REGURGITATION
Regurgitation, the passage of refluxed gastric contents into
the pharynx or mouth, is physiological. Most regurgitation
episodes occur during the postprandial period and cause
few or no other symptoms (8). The five statements related to
regurgitation and the associated voting results are listed in
Table 1.
According to the Rome III criteria, regurgitation in an
infant of between three weeks and 12 months of age
includes: regurgitation two or more times per day for three
weeks or more and an absence of nausea, hematemesis,
aspiration, apnoea, failure to thrive, difficulty in feeding or
swallowing and abnormal posture (3). More than 50% of
three to four-month-old infants regurgitate daily, fulfilling
the Rome III criteria (8). At least two studies have showed
that four or more episodes of regurgitation occurred in
about 20% of all infants and that 20% of mothers sought
medical help for this (8). Investigations are not recom-
mended to diagnose regurgitation. Differential diagnoses
should be considered in infants who are younger than one
week and older than six months, as physiological regurgi-
tation rarely starts before the age of one week or after six
months (8).
The management of regurgitation is as follows (Fig. S1).
In infants with frequent and troublesome regurgitation, a
complete medical history and physical examination is
warranted to rule out organic disease. As physiological
regurgitation should not be diagnosed in an infant with
vomiting and poor weight gain, anthropometry is of major
importance (8). The management of regurgitation starts
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with reassuring parents, by providing information on the
natural history of regurgitation and correct formula prepa-
ration if the infant is not breastfed, together with advice on
how overfeeding may exacerbate symptoms (8). Regurgita-
tion is not a reason to stop breastfeeding. The nutritional
management of regurgitation consists of correcting the
frequency and volume of feeds, if necessary (8). Thickened
formula or antiregurgitation formula decreases regurgita-
tion (8). Placing infants in a prone, anti-Trendelenburg
position cannot be recommended because of the risk of
sudden infant death syndrome (SIDS) (8). However, there
is limited evidence for some efficacy of an antiregurgitation
bed with an angle of 40° anti-Trendelenburg (16). Putting
the infant to sleep on its side has also been recommended,
but is associated with an intermediate risk of SIDS, between
prone and supine sleeping (17). Proton pump inhibitors do
not decrease infant regurgitation, crying, distress or irri-
tability (18). There is no indication for drug treatment in
‘happy spitters’ or in infants with troublesome regurgitation.
Commercial antiregurgitation formulae contain different
thickening agents, such as processed rice, corn or potato
starch, guar gum or locust bean gum. If a commercial
antiregurgitation formula is not available, a thickening
product may be added to standard formula. Cereals increase
the infants’ caloric intake, possibly inducing excessive
weight gain and altering the fat and protein energy ratio.
Locust bean gum does not increase the caloric density, but
may cause bloating (19). Home thickening of a regular
formula increases the osmolarity, which may in itself induce
reflux by increasing the number of transient lower oeso-
phageal sphincter relaxations (8). Infants with persistent
regurgitation and/or vomiting should be referred to a
paediatric gastroenterologist (8).
A limited number of studies have suggested that specific
probiotics, namely Lactobacillus (L.) reuteri DSM 17938,
and prebiotics prevent regurgitation (20,21). L. reuteri DSM
17938 accelerates gastric emptying. The gastric emptying of
a partial protein hydrolysate is faster than that of intact
protein, which may decrease regurgitation (22). CMA
should be suspected in an infant with persistent and
recurrent regurgitation, especially when it is associated
with other manifestations of allergic disease, such as atopic
dermatitis and/or wheezing. These infants should be
referred to a paediatric allergist for appropriate diagnosis
and management.
INFANTILE COLIC
The historic definition of infantile colic consists of crying
lasting three or more hours a day, at least three days a week
for at least three weeks (3). The six statements related to
infantile colic, and their voting results, are listed in Table 2.
In 2006, the Rome III criteria defined infantile colic as:
‘episodes of irritability, fussing or crying that begin and end
for no apparent reason and last at least three hours a day, at
least three days a week, for at least one week in an
apparently healthy infant with a normal clinical examina-
tion’ (3). According to a thorough analysis of the literature,
the median incidence of infantile colic was about 30% (23)
and it was reported to occur as frequently in breast as
bottle-fed infants and equally in both sexes.
The cardinal manifestation of infantile colic is excessive,
persistent, inconsolable or unsoothable loud crying, espe-
cially in the late afternoon. During each episode the child
appears irritable, distressed and fussy, flexes the hip joints,
becomes red-faced and has episodes of borborygmi.
Multiple aetiologies have been proposed. These include
altered gastrointestinal function, food intolerance, tran-
sient low lactase activity, CMA, GOR or GOR disease,
intestinal dysbiosis, parental coping, anxiety, depression,
absence of mother–child reciprocity and the risk of child
abuse.
The management of infantile colic is as follows (Fig. S2).
There are no uniform criteria for a specific therapeutic
approach. The first recommended step is to look out for
potential warning signs that may indicate organic disease. If
these are not present, the feeding technique should be
evaluated and the carers should be reassured and sup-
ported. Parents should be educated to recognise signs of
hunger and fatigue and instructed about structure and
Table 1 Statements and voting results on regurgitation
Stat Consensus Mean
1 Otherwise, healthy infants, who present with four or more episodes of regurgitation
per day during at least two weeks, and in whom the onset is either after the age of
one week or before the age of six months, should be considered as presenting with
physiological regurgitation and should be managed by parental reassurance. (≥4
episodes/d, >2 weeks duration; onset > 1 week and < 6 months of age).
Yes (19/22)
Agree: 86%
7.36
2 Diagnostic investigations are not indicated for the diagnosis and management of
‘troublesome regurgitation’
Yes (20/22)
Agree: 91%
7.36
3 Antiregurgitation formula may be considered in infants with physiological regurgitation Yes (20/22) Agree: 91% 7.41
4 Drug treatment is not indicated in the management of physiological regurgitation Yes (22/22)
Agree 100%
8.68
5 Drug treatment is not indicated in the management of physiological and
troublesome regurgitation
Yes (17/22)
Agree 77%
7.18
Stat: statement.
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regularity. General advice emphasising the self-limiting
nature of the condition is important.
Cows’ milk elimination and other dietary interventions
Infantile colic is not a reason to stop breastfeeding.
However, in selected infants with excessive irritability and
crying it may be recommended that the lactating mother
excludes dairy products for two to four weeks and then
reintroduces them. In selected formula-fed infants, there is
some evidence that an extensively hydrolysed protein
formula reduces infantile colic (10). If the diagnosis of
CMA cannot be made by a specialist, it is preferable to
consider infantile colic as a cows’ milk-related symptom.
With regard to other dietary interventions, soy-based
formula is not recommended, although low-quality studies
have reported a reduction in crying time (10). Reviews have
suggested that partially hydrolysed protein formula could be
beneficial if CMA is not a potential cause of infantile colic
(10,24). These formulae are often lactose-reduced or
lactose-free and contain prebiotics or probiotics, which
may have contributed to a reduction in crying time (10). A
meta-analysis showed that L. reuteri DSM 17938 reduced
infantile colic in exclusively breastfed infants (12), while a
study in mainly formula-fed infants did not show this (25).
One study also showed a reduction in maternal depression
(26). The same probiotic strain was shown to significantly
prevent the onset on infantile colic in formula and breastfed
infants (20,27).
A Latin American expert group concluded that there was
grade 1a evidence for L. reuteri DSM 17938 in the preven-
tion of infantile colic and grade 1b evidence for its
treatment, although the mechanism of action that explains
the efficacy of this probiotic remains unclear (28). However,
these findings should not be extrapolated to other probi-
otics, as the efficacy was only demonstrated in breastfed
infants and there were no data relating to the probiotic
being added to infant formula. Therefore, the use of
L. reuteri DSM 17938 in IC should be considered, but is
not recommended.
Although the addition of prebiotics and probiotics to
infant formula has not been shown to decrease infantile
colic, the evidence seems slightly better for beta-palmitate.
One double-blind, placebo-controlled trial, showed a
significant decrease in infantile colic within one week
of intervention with a partial hydrolysate, with high
b-palmitate and a specific prebiotic mixture of galacto and
fructo-oligosaccharides (29). However, one trial was
considered insufficient for a recommendation.
Lactase or reduced lactose are other dietary options that
have been explored. A limited number of studies have
suggested that transient low lactase activity could trigger
excessive crying (10,30). Lactose-free or soy-based formulae
have not been consistently demonstrated to be beneficial for
patients with infantile colic. The selection of patients is
likely to be a major bias in these studies. After some initial
enthusiasm about the role of lactase treatment, negative
results have suggested that lactose plays a minor role in
infantile colic (10). Although a UK recommendation sug-
gested a one-week trial of lactase drops in breastfed and
formula-fed infants, the evidence for this recommendation
was limited (31). A preventative trial with a formula
containing a stable lactase as the result of a fermentation
process indicated a decreased incidence of infant crying at
the age of four weeks (32). There was insufficient evidence
to recommend a trial of lactase or reduced lactose formula
in every infant presenting with infantile colic, although this
was a safe intervention.
Medication
Proton pump inhibitors have failed to decrease infant
distress in infantile colic (18). Anti-acid medications were
not indicated in infantile colic when GOR disease was not
diagnosed. Cimetropium caused lethargy, motion sickness
and somnolence (33). Hypertonic glucose solutions showed
varying effects on crying time (34). Fennel extracts and
sucrose solutions had some benefit (35). Allopathic drugs
were not proved to be effective (simethicone) and some of
them caused serious adverse reactions (dicyclomine) (36).
Table 2 Statements and voting results on infantile colic
Stat Consensus Mean
6 Evidence suggests that the use of extensively hydrolysed infant formula for a formula-fed baby and a cows’
milk free diet for a breastfeeding mother may be beneficial to decrease infantile colic. However,
these data reflects selected infant populations
Yes (21/22)
Agree 95%
7.73
7 There is convincing data that L. reuteri DSM 17938 decreases infantile colic in well selected
breastfed infants
Yes (19/22)
Agree 86%
7.54
8 However, there is insufficient data to recommend L. reuteri DSM 17938 in all colicky infants Yes (21/22)
Agree 95%
8.32
9 Anti-acid medications are not indicated for colicky infants without manifestations of
gastro-oesophageal reflux disease
Yes (22/22)
Agree 100%
8.73
10 There is limited data reporting positive effects of herbal medicine, such as fennel and peppermint
for treatment of colicky infants
No (15/22)
Agree 68%
6.54
11 However, the evidence of benefit is too limited to recommend herbal medicine such as fennel
and peppermint for alleviating infantile colic
Yes (22/22)
Agree 100%
8.36
Stat: statement; italic: statements on which consensus was not reached.
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In a double-blind study, mentha piperita was shown to
reduce infantile colic (37). An extract of Matricariae
recutita, Foeniculum vulgare and Melissa officinalis
improved infantile colic in breastfed infants (38). However,
evidence was too limited to recommend the use of any of
these herbal medicinal products for infantile colic.
Swaddling and other caregiving interventions
There was insufficient evidence to systematically recom-
mend swaddling, although the technique was reported to be
of some benefit in infants who were less than eight weeks
old (39). Studies have evaluated the role of carers’ support,
counselling therapy, car rides during colic episodes and a
reduction in stimulating actions such as changing diapers
and chiropractic and spinal massages. Unfortunately, none
of these trials were of sufficient methodological quality (10).
Our conclusion about infantile colic
Infantile colic is a multifactorial condition and it is unlikely
that a single intervention will significantly reduce it in an
unselected population. In infants with proven CMA and
infantile colic, the correct treatment is extensively hydrol-
ysed formula or, if that cannot be tolerated, an amino acid-
based formula (5). There has been insufficient evidence to
enable us to recommend a trial with L. reuteri DSM 17938
or lactase, although neither induced adverse effects.
CONSTIPATION
Healthcare practitioners must be aware of normal infant
defecation patterns to adequately educate and advise
parents (3). One study showed that infants who had colic
symptoms in the first two months had less frequent
defecation during the first two years of life (40). The second
month of life was unique in the sense that the frequency of
stooling decreased to half of the previous month (40). The
four statements related to constipation, and their voting
results, are listed in Table 3.
Information should be obtained regarding the duration of
the condition, the frequency of bowel movements, the
consistency, colour and size of the stools, whether defeca-
tion is painful and the presence of blood and mucus. This
information will help to make the distinction between
functional constipation and constipation due to organic
disease. The Amsterdam stool scale may be a useful tool (9).
According to the Rome III criteria, the definition of
functional constipation includes at least two of the follow-
ing criteria in an apparently healthy infant: (i) two or fewer
defecations per week; (ii) at least one episode per week of
incontinence after the acquisition of toileting skills (not
relevant in infants); (iii) history of excessive stool retention;
(iv) history of painful or hard bowel movements; (v)
presence of a large faecal mass in the rectum; (vi) history
of large-diameter stools that may obstruct the toilet (not
relevant in infants) (3).
Crying and straining associated with defecation of soft
stools in otherwise healthy infants who are less than six
months of age is defined as functional dyschezia, which is a
different condition from constipation. Dyschezia resolves
with time without the need for any intervention (3).
Hard stools occur in only 1% of exclusively breastfed
infants compared to 9.2% of standard formula-fed infants
who do not receive prebiotic or probiotic supplements. (9).
While breastfed infants generally produce soft stools rang-
ing from one per week up to six or eight per day, extremes of
up to 12 times a day or once every three to four weeks have
been reported (3,9). Firm or hard stools often occur when
breast milk is switched to infant formula or after the
introduction of solids. Harder stools are frequent in infants
fed with formula containing vegetable oil that is rich in
palmitic acid that is found mainly at the stereospecific
numbering (Sn) positions Sn-1 and Sn-3. In mother’s milk,
palmitic acid is mainly in the Sn-2 position (9). The Sn-1
and Sn-3 positions favour the formation of calcium soaps,
responsible for the hard stools, whereas the Sn-2 position is
not associated with this problem.
The prevalence rate for constipation in the first year of
life has been reported to be 2.9%, increasing up to 10.1% in
the second year (9).
Infants under one year of age are referred for suspected
functional constipation because of pain, consistency and
frequency of stools. Accompanying symptoms may include
irritability, decreased appetite and early satiety, which
rapidly disappear after passing stools (3,9).
The management of constipation is as follows (Fig. S3). A
thorough medical history and physical examination are the
cornerstones for diagnosing functional constipation. Failure
to pass meconium within 24 hours of birth should raise
suspicion of Hirschsprung’s disease or cystic fibrosis (9). If
an organic cause is not suspected, there is no indication for
laboratory or radiographic testing (9). The patient should be
referred if they are failing to thrive, have intermittent
diarrhoea or abdominal distension (9). At some time in the
clinical assessment, every infant with functional constipa-
tion should have a digital rectal examination (9). The
anorectal examination should evaluate perianal sensitivity,
Table 3 Statements and voting results on infant constipation
Stat Consensus Mean
12 Lactulose may be considered as an
intervention for functional constipation
Yes (21/22)
Agree 95%
8.09
13 Macrogol (polyethylene glycol, PEG)
may be considered as an intervention
for functional constipation for infants
over six months of age
Yes (21/22)
Agree 95%
8.36
14 An extensively hydrolysed infant formula
may be considered as an intervention
for functional constipation for two to
four weeks, followed by a challenge
with standard cows milk infant formula
in formula-fed infants
No (16/22)
Agree 73%
6.27
15 Rectal treatment with glycerine suppository
should be restricted to providing acute
relief in functional constipation
Yes (20/22)
Agree 91%
7.82
Stat: statement; italic: statements on which consensus was not reached.
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anal calibre, position and tone and the presence of an anal
wink, fissure or prolapse (3,9).
The first step in the management of functional constipa-
tion is parental education and reassurance (3,9). If the
probability of an organic condition is low, reassurance and
close follow-up are sufficient. Dietary changes and corn
syrup resolve constipation in 25% of cases and laxatives
work in 92% (9). In some infants constipation is related to
the intake of CMP, although there is no consensus that
extensively hydrolysed formula or soy formulae are indi-
cated for all constipated infants (9). In children with food-
related chronic constipation, an increase in both rectal mast
cell density and spatial interactions between mast cells and
nerve fibres correlates with anal motor abnormalities (41).
In infants who are not constipated, using a formula
enriched with prebiotics and/or probiotics increases the
frequency of defecation and softens the stools (42,43). An
underpowered study performed with a partial hydrolysate, a
prebiotic and b-palmitate, which is palmitic acid enriched at
the Sn-2 position, showed a trend for a softer stool
consistency (44).
There is no evidence to support the use of mineral water
rich in magnesium to prepare infant formula. Some anti-
constipation formulae have a high content of magnesium,
albeit within the regulatory limits (9,45). L. reuteri DSM
17938 increases stool frequency in normal infants (20), but
only one study has shown that L. reuteri DSM 17938
increased bowel movements in constipated infants, without
any difference in consistency and crying episodes (46).
Lactulose is effective, but causes flatulence (9). Both milk
of magnesia and polyethylene glycol are efficient and safe for
infants and toddlers (47). Polyethylene glycol is registered in
most countries from the age of six months, is at least as
effective as lactulose and causes fewer side effects (9).
Juices containing sorbitol, such as prune, pear and apple
juices, decrease constipation but induce a risk of unbal-
anced nutrition (9). Glycerine suppositories can be helpful
if acute relief from rectal emptying is needed (9). Evidence
does not support the use of mineral oil, as this risks lipoid
pneumonia due to aspiration, or enemas such as phosphate
in young infants (9).
THE ROLE OF COWS’ MILK-RELATED SYMPTOMS AND CMA
CMA is significantly less common than the FGIDs discussed
above and occurs in only 3–5% of formula-fed infants and in
0.5% of breastfed infants (5,13). Three related statements
and their voting results are listed in Table 4. CMA often
presents with gastrointestinal manifestations such as regur-
gitation, vomiting and abnormal defecation, although these
are rarely the single manifestation. Most infants with CMA
present a combination of symptoms involving different
organ systems. Symptoms of CMA and FGID overlap and
diagnostic tests do not reliably differentiate between both of
them. Therefore, if the diagnosis of CMA cannot be
confirmed by a specialist, it is preferable to designate these
symptoms as cows’ milk related. A decrease of symptoms
with an extensively hydrolysed formula should not be
considered as proof of CMA, as gastric emptying is enhanced
and stools are softer when this is administered (48).
Classification and clinical features
According to the definition proposed by the World Allergy
Organization, CMA is a hypersensitivity reaction caused by
specific immunological mechanisms to one or more of the
proteins present in cows’ milk (49). IgE-mediated CMA is
characterised by an immediate reaction and is often
associated with atopic dermatitis, asthma, and/or, allergic
rhinitis. Gastrointestinal symptoms such as regurgitation,
vomiting, colic and diarrhoea accompany systemic mani-
festations of the skin such as urticaria and angio-oedema
and the respiratory tract such as rhinitis, wheezing and
stridor. There are also shock-like symptoms, which occur
usually within minutes or up to two hours later (5,13).
Mixed immunoglobulin E (IgE) and non-IgE-mediated
CMA constitute a group of disorders that are well defined
clinically, but their immunological mechanisms are not well
understood. Most of the gastrointestinal symptoms are non-
IgE mediated, making it difficult to differentiate functional
gastrointestinal symptoms from CMA. Children with a
positive food challenge often present with one or more
FGIDs. Therefore, it is more appropriate for primary
healthcare practitioners to consider that these symptoms
are related to the ingestion of CMP rather than proof of
CMA.
Diagnosis and management of CMA and cow’s milk-
related symptoms
Eliminating cows’ milk and then carrying out an oral
challenge is the standard diagnostic test for CMA or for any
symptom related to the ingestion of cows’ milk protein.
Both over-diagnosis and under-diagnosis have an adverse
impact on the child’s growth (50). Skin prick testing and
specific IgE tests indicate sensitisation to cows’ milk
protein, while negative tests do not exclude CMA (5,51).
Total IgE has a poor specificity for the diagnosis of CMA.
Specific IgE and the diameter of the skin prick testing
provide information on the prognosis: the higher the
Table 4 Statements and voting results on CMA
Stat Consensus Mean
16 The first treatment choice of CMA in
formula-fed infants is an extensive
cows’ milk based hydrolysate
Yes (22/22)
Agree 100%
8.64
17 If extensive cow’s milk based hydrolysates
are not available, too expensive or not
accepted or tolerated because of the taste,
extensive rice hydrolysates and/or soy
infant formulae are a valid second choice
Yes (20/22)
Agree 91%
7.91
18 There is insufficient data to state that
soy-based infant formula would be more
unsafe for infants younger than six months
than for older infants
Yes (20/22)
Agree 91%
7.36
Stat: statement.
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specific IgE and/or the larger the diameter of the skin
reaction, the longer it will take until tolerance to CMP
develops (52). Atopy patch testing is not a recommended
procedure (5).
Children with cows’ milk-related symptoms or CMA
should be monitored for the development of tolerance
through repeated oral food challenges (5).
Regarding formula replacement, many guidelines have
recommended extensively hydrolysed formula as the first
option (5,13,52,53). We refer to previously published
algorithms (5). According to the World Allergy Organiza-
tion guidelines, Diagnosis and Rationale for Action against
Cows’ Milk Allergy recommend extensively hydrolysed
formula over soy formula in IgE-mediated CMA, but stress
the need for more data, stating: ‘there is very sparse
evidence suggesting a possible benefit from using eHF
compared to soy formula’ (49). There is limited evidence
that the addition of prebiotics or probiotics, namely
L. rhamnosus GG or Bifidobacteria breve, to an extensively
hydrolysed formula offers any additional benefits (53,54). In
an open study, it was suggested that L. rhamnosus GG
induced more rapid tolerance (53). However, results
from an open study provide insufficient evidence for a
recommendation.
Soy is the second option, especially if extensively
hydrolysed formula is not available, if it is too expensive
or if the child refuses to drink it (5). The Agence Francaise
de Securite Sanitaire des Aliments underlined the limited
knowledge and uncertainties regarding the presence of
isoflavones in soy formulae (55). The American Academy of
Pediatrics concluded that 10–14% of infants with CMA
would become sensitised to soy and that this happened
more frequently in non-IgE-mediated CMA (56). According
to a recent meta-analysis the prevalence of soy allergy was
0.5% in the general population, but the prevalence of
sensitisation after the use of soy infant formula was 8.7%
(57). The risk of developing sensitisation to soy should be
considered according to the cost-efficacy-risk ratio, which
differs according to the socio-economic situation. Although
soy protein has been used in infant feeding for more than
100 years, its popularity varies substantially in different
parts of the world (57). Soy-based infant formula has a high
content of isoflavones, which have been shown to induce
oestradiol-like effects in animal models (58).
Extensive hydrolysates from rice protein, which are on
the market in a growing number of countries, may gain
greater scientific support as the evidence of their efficacy is
growing (59) and they are cheaper than extensively hydrol-
ysed formula. However, the level of arsenic content in
rice-based infant formula should be declared (60).
Although regurgitation, constipation or infantile colic in
infants may be related to the ingestion of CMP, the immune
mechanisms involved can rarely be demonstrated. There-
fore, these infants should not be considered as suffering
from CMA but as infants presenting with cows’ milk
ingestion-related symptoms. It is important that the health-
care practitioner explains this to the parents, as the long-
term outcomes of CMA or food-related symptoms differ.
CONCLUSION
Infants presenting with gastrointestinal problems such as
regurgitation, infantile colic and/or defecation problems
often undergo a series of unnecessary investigations and
medical treatments. Overall, medication has failed to
deliver significant improvements in these conditions. The
practical algorithms presented in this paper focus on
reassurance, education and dietary intervention and will
assist primary healthcare practitioners in the diagnosis and
management of functional gastrointestinal manifestations
in infants who are less than 12 months old. The diagnosis
and management of CMA are challenging because there are
no specific symptoms or diagnostic tests available, other
than dietary exclusion and oral challenges. Our proposed
algorithms are based on the evidence, when it was
available, and expert consensus when evidence was not
available.
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